Cantor Fitzgerald analyst Steve Seedhouse raised the firm’s price target on BioCryst (BCRX) to $26 from $24 and keeps an Overweight rating on the shares. BioCryst is buying top pick Astria Therapeutics (ATXS) for $700M in enterprise value, and the deal is a “terrific” value for BioCryst, even before accounting for essentially total SG&A synergy, and it allows BioCryst to protect and extend its core HAE commercial leadership position through navenibart’s loss of exclusivity in 2042, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst’s Strategic Acquisition of Astria Therapeutics: Enhancing HAE Portfolio with Navenibart
- BioCryst price target raised to $27 from $17 at Citizens JMP
- BioCryst reinstated with a Buy at TD Cowen
- BioCryst weakness presents ‘compelling’ buying opportunity, says RBC
- BioCryst’s Strategic Acquisition of ATXS: A Catalyst for Long-Term Growth and Profitability